Lesson
Read the Scaffold Before the Drug Name
NRTIs mimic the building blocks used to synthesize DNA, but their altered sugar or nucleotide architecture changes intracellular activation and prevents productive chain extension.
- Nucleoside analog
- Nucleotide analog
- Sugar modification
- Prodrug
- Active metabolite
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Separate nucleoside from nucleotide
Abacavir, emtricitabine, lamivudine, and zidovudine enter as nucleoside analogs and require intracellular phosphorylation. Tenofovir is an acyclic nucleotide analog delivered through oral prodrugs, so it begins closer to the active nucleotide state.
Find the missing extension chemistry
Natural deoxynucleotides contain the geometry needed to form the next phosphodiester bond. Active NRTI metabolites lack or distort the required three-prime hydroxyl relationship, so incorporation can halt DNA elongation.
Use prodrugs to redirect exposure
TDF and TAF both deliver tenofovir, but their promoieties produce different plasma stability and tissue delivery. The final intracellular inhibitor is tenofovir diphosphate.
Connect analog identity to selectivity
The active metabolite competes at HIV reverse transcriptase more effectively than at many host polymerases. Selectivity is meaningful but incomplete, which is why mitochondrial and organ toxicity remain possible.
Quick check
Lesson
Follow Activation to Chain Termination
The administered molecule is not the final inhibitor. Intracellular enzymes create the active triphosphate or diphosphate that competes with a natural substrate at reverse transcriptase.
- Phosphorylation
- Triphosphate
- Diphosphate
- Competitive substrate
- Chain termination
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Activate inside the cell
Host kinases convert nucleoside analogs through mono, di, and triphosphate states. Tenofovir prodrugs release tenofovir, which is phosphorylated to the active diphosphate.
Compete at reverse transcriptase
The active analog competes with a natural deoxynucleotide at the polymerase active site. This substrate strategy differs from the allosteric binding used by NNRTIs.
Terminate after incorporation
Reverse transcriptase can incorporate the analog into viral DNA. The altered scaffold then prevents or severely impairs addition of the next nucleotide.
Preserve the combination context
NRTIs suppress reverse transcription but have a relatively low resistance barrier when used without a complete active regimen. Their value depends on sustained intracellular exposure and active companion drugs.
Quick check
Lesson
Protect the Backbone From Functional Monotherapy
An NRTI backbone is a pharmacologic system, not a decorative pair. Activity depends on mutation pattern, companion-drug activity, adherence, and the full treatment history.
- Backbone
- Low barrier
- M184V
- K65R
- Thymidine analog mutations
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Define the backbone
Many current regimens combine two NRTIs with a high-barrier anchor drug. Current recommended initial backbones commonly pair TAF or TDF with emtricitabine or lamivudine.
Recognize rapid selection
M184V or M184I can emerge with lamivudine or emtricitabine pressure and causes high-level resistance to those drugs. K65R reduces activity of tenofovir, abacavir, lamivudine, and emtricitabine to different degrees.
Interpret thymidine analog pathways
Sequential thymidine analog mutations can reduce zidovudine activity and create broader cross-resistance. Mutation combinations can interact, so a single mutation should not be translated into an isolated yes or no drug list.
Use expert synthesis in failure
Review every regimen, genotype, phenotype when available, adherence pattern, interaction, and viral-load trajectory. Construct a complete suppressive regimen rather than protecting one new drug with a failing backbone.
Quick check
Lesson
Compare TDF and TAF as Delivery Systems
TDF and TAF produce the same active intracellular metabolite but differ in stability, dose, plasma tenofovir exposure, target-cell delivery, and interaction constraints.
- TDF
- TAF
- Plasma tenofovir
- Intracellular tenofovir diphosphate
- Transporters
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Trace TDF delivery
TDF is converted relatively quickly after absorption and produces higher circulating tenofovir exposure. It remains an effective and widely used option, including in recommended initial backbones.
Trace TAF delivery
TAF is more stable in plasma and is activated more efficiently within target cells. It reaches higher intracellular tenofovir diphosphate with a much lower administered dose and lower plasma tenofovir exposure.
Do not compare milligrams directly
Different prodrug efficiency means milligram dose is not a measure of antiviral potency across TDF and TAF. Compare the approved product, companion drugs, organ function, and interaction profile.
Respect product-specific interactions
TAF is a transporter substrate, and strong P-glycoprotein inducers can reduce exposure. Boosted products can alter the approved TAF dose. Use the exact label and interaction table for the complete product.
Quick check
Lesson
Use TDF With Renal and Bone Accountability
TDF is effective and can provide favorable lipid effects, but higher plasma tenofovir exposure increases concern for proximal tubular injury and bone mineral loss.
- Proximal tubule
- Fanconi syndrome
- Creatinine clearance
- Bone mineral density
- Nephrotoxin
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Recognize proximal tubular injury
TDF can cause increased creatinine, renal insufficiency, acute kidney injury, and proximal tubulopathy. Fanconi syndrome can produce urinary wasting of phosphate, glucose, bicarbonate, potassium, amino acids, and other solutes.
Build renal surveillance
Assess estimated kidney function before and during therapy. Use urine protein, urine glucose, and serum phosphorus when risk or findings support proximal tubular evaluation. A normal glucose level does not make urine glucose irrelevant.
Protect bone health
Renal phosphate wasting and direct exposure effects can contribute to bone mineral loss and osteomalacia. Evaluate fracture risk, bone symptoms, nutrition, vitamin D, and bone density when clinically indicated.
Use the exact renal table
Single-agent TDF can use interval adjustment in renal impairment, while fixed-dose combinations have their own cutoffs. Avoid collapsing every product into one creatinine-clearance rule and avoid unnecessary nephrotoxic exposure.
Quick check
Lesson
Select TAF Without Calling It Risk Free
TAF generally improves kidney and bone markers compared with TDF, but regimen choice still depends on kidney function, interactions, HBV, lipid and weight priorities, and the exact coformulation.
- Renal biomarkers
- Bone density
- Lipids
- Weight
- Combination product
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Use comparative safety accurately
Clinical trials generally show smaller declines in kidney biomarkers and bone mineral density with TAF than with TDF. Proximal tubulopathy remains possible and monitoring still follows risk.
Track metabolic differences
TDF often produces lower total cholesterol, LDL, and triglycerides than TAF. Weight and lipid changes after a switch can reflect removal of TDF effects, the new regimen, or both.
Read the coformulation
For HIV treatment, TAF is used in combination products. Renal thresholds, food instructions, interacting drugs, and the TAF dose differ across products, especially with pharmacokinetic boosters.
Preserve HBV activity
TAF contributes HBV activity when paired appropriately in a complete HIV regimen. Do not stop it during simplification without first securing adequate HBV therapy and post-change monitoring.
Quick check
Lesson
Differentiate Closely Related Cytidine Analogs
Lamivudine and emtricitabine are structurally related cytidine analogs with overlapping HIV and HBV activity, but they remain separate products with different labels and should not be combined.
- Lamivudine
- Emtricitabine
- Cytidine analog
- Renal elimination
- Hyperpigmentation
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Connect shared chemistry
Both agents are cytidine analogs that become active triphosphates and inhibit reverse transcriptase through incorporation and chain termination. They are commonly paired with tenofovir, not with each other.
Use them as alternatives, not partners
Lamivudine and emtricitabine have overlapping resistance and activity. Combining them does not create a rational two-drug backbone and can duplicate toxicity without meaningful added coverage.
Apply renal dosing carefully
Both are predominantly renally eliminated and require adjustment as single agents when kidney function declines. Fixed-dose products may not permit the same adjustment, so the complete label matters.
Recognize distinguishing details
Emtricitabine can cause skin hyperpigmentation, including palms and soles. Lamivudine appears in both HIV-dose and lower-dose HBV products, and the HBV formulation must not be substituted for HIV treatment.
Quick check
Lesson
Protect Both Viruses During Every Regimen Change
Tenofovir, lamivudine, and emtricitabine can suppress HBV, so HIV regimen construction and discontinuation can create HBV resistance or severe flare if the second virus is ignored.
- HBsAg
- HBV DNA
- Dual HBV activity
- M184V
- Withdrawal flare
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Build dual-active therapy
When HIV and active HBV coexist, the ART backbone generally includes TAF or TDF plus lamivudine or emtricitabine. This provides two HBV-active drugs inside a fully suppressive HIV regimen.
Avoid single-agent HBV pressure
Lamivudine or emtricitabine alone is not adequate long-term HBV therapy because HBV resistance emerges readily. HBV-active drugs should also not be used without a complete HIV regimen in a person with HIV.
Plan every discontinuation
Stopping tenofovir, lamivudine, or emtricitabine can trigger severe acute HBV exacerbation. Secure replacement HBV therapy when needed and monitor liver tests, symptoms, and HBV markers after the change.
Distinguish product doses
The lower-dose lamivudine product labeled for HBV does not supply the HIV treatment dose. Coinfection management must use doses and products that fully treat HIV while also maintaining HBV activity.
Quick check
Lesson
Make Abacavir Hypersensitivity Preventable
Abacavir can cause a multisystem hypersensitivity reaction that becomes more dangerous with re-exposure. HLA-B*5701 screening reduces risk but does not replace symptom recognition.
- Abacavir
- HLA-B*5701
- Hypersensitivity
- Never rechallenge
- Cardiovascular signal
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Test before exposure
Obtain HLA-B*5701 before starting abacavir. A positive result contraindicates the drug and should be documented clearly in the allergy and medication record.
Recognize the syndrome
Fever, rash, constitutional symptoms, gastrointestinal symptoms, and respiratory symptoms can occur in combinations. Reactions often begin during the first six weeks, but timing alone cannot establish or exclude the diagnosis.
Never test by rechallenge
If hypersensitivity is suspected, stop abacavir and never restart it. Rechallenge can provoke a more rapid, severe, or fatal reaction, including hypotension.
Place cardiovascular uncertainty honestly
Some observational studies report increased cardiovascular events with recent abacavir exposure, while other studies do not. Current NIH guidance treats this as an ongoing concern and generally favors alternatives when cardiovascular risk is substantial.
Quick check
Lesson
Learn From the Toxicity History
Zidovudine, didanosine, and stavudine shaped HIV treatment but are no longer routine United States choices because safer and more convenient options have displaced their toxicity burden.
- Zidovudine
- Anemia
- Neutropenia
- Didanosine
- Stavudine
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Monitor zidovudine marrow effects
Zidovudine can cause macrocytic anemia and neutropenia. Rising mean corpuscular volume can reflect exposure, but it does not prove effective suppression or replace CBC monitoring.
Recognize myopathy and administration burden
Long-term zidovudine can produce myopathy, and twice-daily use adds burden. Specialized perinatal use has changed over time and must follow current perinatal guidance and viral-load context.
Identify didanosine toxicity
Didanosine is associated with pancreatitis, peripheral neuropathy, lactic acidosis, hepatic injury, and complex interaction and administration problems. It is discontinued in the United States.
Identify stavudine toxicity
Stavudine produces peripheral neuropathy, lipoatrophy, pancreatitis, and mitochondrial toxicity. It is discontinued in the United States and should be recognized in historical treatment records.
Quick check
Lesson
Recognize Mitochondrial Injury Before Collapse
NRTI inhibition of host mitochondrial DNA polymerase gamma can impair oxidative metabolism and produce a linked syndrome of hyperlactatemia, acidosis, hepatic steatosis, myopathy, neuropathy, and fat redistribution.
- Polymerase gamma
- Lactic acidosis
- Hepatic steatosis
- Myopathy
- Lipoatrophy
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Connect the host target
Although NRTIs favor viral reverse transcriptase, some metabolites can inhibit mitochondrial polymerase gamma. Mitochondrial DNA depletion impairs oxidative phosphorylation and shifts metabolism toward lactate accumulation.
Recognize clinical warning signs
Persistent nausea, vomiting, abdominal pain, unexplained fatigue, weight loss, dyspnea, weakness, hepatomegaly, or rising liver tests can precede severe lactic acidosis and hepatic steatosis.
Act on the syndrome
Stop the suspected offending regimen and obtain urgent evaluation when symptomatic lactic acidosis or pronounced hepatotoxicity is suspected. Measure acid-base status, lactate, liver injury, organ perfusion, and competing causes.
Compare current and legacy risk
Severe mitochondrial syndromes are far less common with current lamivudine, emtricitabine, abacavir, and tenofovir strategies than with older didanosine, stavudine, and zidovudine exposure, but the class warning remains clinically meaningful.
Quick check
Lesson
Build the NRTI Plan Around the Whole Person
The final NRTI choice joins virologic activity with HBV, kidney, bone, cardiovascular, metabolic, reproductive, interaction, formulation, and access realities.
- Baseline data
- Product label
- Pregnancy
- Lactation
- Monitoring plan
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Verify virologic fit
Review current and historical resistance, prior PrEP or ART exposure, viral load, and companion-drug activity. Do not assume that a familiar coformulation remains fully active.
Match organ and coinfection priorities
Use HBV status, estimated kidney function, urine findings, bone health, cardiovascular risk, lipids, marrow status, and interacting nephrotoxins or transport inducers to compare options.
Use current reproductive guidance
Both TAF and TDF are recommended NRTI options in pregnancy in current United States guidance, and several NRTIs have extensive pregnancy experience. Use current perinatal tables for exact regimen selection, dosing, intrapartum decisions, and infant feeding counseling rather than old pregnancy letters.
Close the monitoring loop
Name the response marker, organ tests, symptoms that require urgent contact, refill plan, and next review. Current labeling controls exact renal thresholds and coformulation instructions because fixed-dose products cannot always be adjusted component by component.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 208 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.